vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Delek Logistics Partners, LP (DKL). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $154.7M, roughly 1.2× Delek Logistics Partners, LP). On growth, Delek Logistics Partners, LP posted the faster year-over-year revenue change (518.9% vs 57.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -23.5%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Delek Logistics Partners, LP is a U.S.-based midstream energy logistics enterprise that offers storage, transportation, and distribution services for crude oil, refined petroleum products, and renewable fuels. It mainly serves downstream energy operators, retail fuel networks and industrial clients across the U.S. Gulf Coast and Southeast regions.

AXSM vs DKL — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.2× larger
AXSM
$191.2M
$154.7M
DKL
Growing faster (revenue YoY)
DKL
DKL
+461.4% gap
DKL
518.9%
57.4%
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
48.1%
-23.5%
DKL

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AXSM
AXSM
DKL
DKL
Revenue
$191.2M
$154.7M
Net Profit
$32.4M
Gross Margin
-62.0%
Operating Margin
-33.1%
25.9%
Net Margin
20.9%
Revenue YoY
57.4%
518.9%
Net Profit YoY
EPS (diluted)
$0.60

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
DKL
DKL
Q1 26
$191.2M
$154.7M
Q4 25
$196.0M
$255.8M
Q3 25
$171.0M
$261.3M
Q2 25
$150.0M
$246.3M
Q1 25
$121.5M
$249.9M
Q4 24
$118.8M
$209.9M
Q3 24
$104.8M
$214.1M
Q2 24
$87.2M
$264.6M
Net Profit
AXSM
AXSM
DKL
DKL
Q1 26
$32.4M
Q4 25
$-28.6M
$47.3M
Q3 25
$-47.2M
$45.6M
Q2 25
$-48.0M
$44.6M
Q1 25
$-59.4M
$39.0M
Q4 24
$-74.9M
$35.3M
Q3 24
$-64.6M
$33.7M
Q2 24
$-79.3M
$41.1M
Gross Margin
AXSM
AXSM
DKL
DKL
Q1 26
-62.0%
Q4 25
17.2%
Q3 25
20.6%
Q2 25
25.8%
Q1 25
21.5%
Q4 24
23.4%
Q3 24
22.8%
Q2 24
28.1%
Operating Margin
AXSM
AXSM
DKL
DKL
Q1 26
-33.1%
25.9%
Q4 25
-13.8%
14.2%
Q3 25
-27.0%
17.4%
Q2 25
-24.5%
21.3%
Q1 25
-46.9%
19.0%
Q4 24
-61.1%
18.1%
Q3 24
-59.8%
14.9%
Q2 24
-89.5%
25.9%
Net Margin
AXSM
AXSM
DKL
DKL
Q1 26
20.9%
Q4 25
-14.6%
18.5%
Q3 25
-27.6%
17.4%
Q2 25
-32.0%
18.1%
Q1 25
-48.9%
15.6%
Q4 24
-63.1%
16.8%
Q3 24
-61.7%
15.7%
Q2 24
-91.0%
15.5%
EPS (diluted)
AXSM
AXSM
DKL
DKL
Q1 26
$0.60
Q4 25
$-0.55
Q3 25
$-0.94
Q2 25
$-0.97
Q1 25
$-1.22
Q4 24
$-1.54
Q3 24
$-1.34
Q2 24
$-1.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
DKL
DKL
Cash + ST InvestmentsLiquidity on hand
$305.1M
$9.9M
Total DebtLower is stronger
$70.0M
$2.3B
Stockholders' EquityBook value
Total Assets
$713.6M
$2.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
DKL
DKL
Q1 26
$305.1M
$9.9M
Q4 25
$322.9M
$10.9M
Q3 25
$325.3M
$6.9M
Q2 25
$303.0M
$1.4M
Q1 25
$300.9M
$2.1M
Q4 24
$315.4M
$5.4M
Q3 24
$327.3M
$7.3M
Q2 24
$315.7M
$5.1M
Total Debt
AXSM
AXSM
DKL
DKL
Q1 26
$70.0M
$2.3B
Q4 25
$2.3B
Q3 25
$2.3B
Q2 25
$2.2B
Q1 25
$2.1B
Q4 24
$1.9B
Q3 24
$1.9B
Q2 24
$1.6B
Stockholders' Equity
AXSM
AXSM
DKL
DKL
Q1 26
Q4 25
$88.3M
Q3 25
$73.7M
Q2 25
$73.1M
Q1 25
$53.2M
Q4 24
$57.0M
Q3 24
$92.9M
Q2 24
$102.9M
Total Assets
AXSM
AXSM
DKL
DKL
Q1 26
$713.6M
$2.9B
Q4 25
$689.8M
$2.8B
Q3 25
$669.3M
$2.7B
Q2 25
$639.8M
$2.8B
Q1 25
$596.7M
$2.4B
Q4 24
$568.5M
$2.0B
Q3 24
$561.5M
$2.0B
Q2 24
$548.2M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
DKL
DKL
Operating Cash FlowLast quarter
$170.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
5.4%
Cash ConversionOCF / Net Profit
5.27×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
DKL
DKL
Q1 26
$170.4M
Q4 25
$-18.7M
$43.2M
Q3 25
$1.0M
$54.9M
Q2 25
$-32.4M
$107.4M
Q1 25
$-43.4M
$31.6M
Q4 24
$-26.2M
$49.9M
Q3 24
$-18.6M
$24.9M
Q2 24
$-30.1M
$87.6M
Free Cash Flow
AXSM
AXSM
DKL
DKL
Q1 26
Q4 25
$-18.7M
$12.6M
Q3 25
$988.0K
$-12.3M
Q2 25
$-32.4M
$-7.1M
Q1 25
$-43.7M
$-23.9M
Q4 24
$-26.2M
$3.9M
Q3 24
$-18.7M
$-31.7M
Q2 24
$-30.2M
$72.5M
FCF Margin
AXSM
AXSM
DKL
DKL
Q1 26
Q4 25
-9.6%
4.9%
Q3 25
0.6%
-4.7%
Q2 25
-21.6%
-2.9%
Q1 25
-36.0%
-9.6%
Q4 24
-22.1%
1.8%
Q3 24
-17.9%
-14.8%
Q2 24
-34.6%
27.4%
Capex Intensity
AXSM
AXSM
DKL
DKL
Q1 26
5.4%
Q4 25
0.0%
12.0%
Q3 25
0.0%
25.7%
Q2 25
0.0%
46.5%
Q1 25
0.3%
22.2%
Q4 24
0.0%
21.9%
Q3 24
0.1%
26.4%
Q2 24
0.1%
5.7%
Cash Conversion
AXSM
AXSM
DKL
DKL
Q1 26
5.27×
Q4 25
0.91×
Q3 25
1.21×
Q2 25
2.41×
Q1 25
0.81×
Q4 24
1.41×
Q3 24
0.74×
Q2 24
2.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Product sales, net$189.4M99%
Royalty revenue and milestone revenue$1.8M1%

DKL
DKL

Third party$105.4M68%
Affiliate$49.2M32%

Related Comparisons